Biocon’s breast cancer biosimilar gets a positive EMA opinion; closer to launching therapy in EU
Pertuzumab biosimilar Pebrilzo gets positive EMA committee opinion, taking Biocon Biologics closer to a European launch.
Attribution
This digest is published with acknowledgment to Business Today. For the complete analysis, headnotes, and citations, please refer to the source.
Read on Business Today
